MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily 20+ Yr Trsy Bull 3X ETF

Direxion Daily Gold Miners Bull 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF

ProShares Ultra Silver

T-REX 2X Inverse Tesla Daily Target ETF

Direxion Daily MSFT Bull 1.5X Shares

Consumer Staples Select Sector SPDR ETF

VanEck Vectors Junior Gold Miners ETF

GraniteShares 1.5x Long Coinbase Daily ETF

Mast Therapeutics, Inc.

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Direxion Daily FTSE China Bull 3X ETF

GraniteShares 2x Long AMZN Daily ETF

Volatility Shares Trust 2x Ether ETF

AXS 2X Innovation ETF

Direxion Daily TSLA Bull 1.5X Shares

ProShares Ultra DJ-AIG Crude Oi

KraneShares CSI China Internet ETF

Click Holdings Limited Ordinary Share

Foot Locker Inc.

Aytu BioPharma Inc.  Common Stock

Gryphon Digital Mining Inc Common Stock

Incannex Healthcare Limited American Depositary Shares

Kindly MD Inc. Common Stock

Asset Entities Inc. Class B Common Stock

LOBO EV TECHNOLOGIES LTD. Ordinary shares

Siyata Mobile Inc. Common Shares

Next Technology Holding Inc. Ordinary Shares

Crown LNG Holdings Limited Ordinary Shares

Luminar Technologies Inc.  Class A Common Stock

UnitedHealth Group Incorporated Common Stock (DE)

Dick's Sporting Goods Inc Common Stock

MicroAlgo Inc. Ordinary Shares

ScanTech AI Systems Inc. Common stock

Oriental Rise Holdings Limited Ordinary Shares

HWH International Inc. Common Stock

Canaan Inc. American Depositary Shares

Plug Power Inc. Common Stock

Click here to get full coverage on Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks

Aytu BioPharma Reports Strong Q3 2025 Earnings  TipRanks

Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks

Click here to get full coverage on Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats E - GuruFocus

Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats E  GuruFocus

Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats E - GuruFocus

Click here to get full coverage on Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary  TradingView

Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps - Investing.com

Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps  Investing.com

Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps - Investing.com

Click here to get full coverage on Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - ACCESS Newswire

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results  ACCESS Newswire

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - ACCESS Newswire

Click here to get full coverage on We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation - simplywall.st

We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation  simplywall.st

We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation - simplywall.st

Click here to get full coverage on Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Stro - GuruFocus

Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Stro  GuruFocus

Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Stro - GuruFocus

Click here to get full coverage on Aytu BioPharma CEO Reveals Growth Strategy at Exclusive Vegas Investor Showcase - Stock Titan

Aytu BioPharma CEO Reveals Growth Strategy at Exclusive Vegas Investor Showcase  Stock Titan

Aytu BioPharma CEO Reveals Growth Strategy at Exclusive Vegas Investor Showcase - Stock Titan

Click here to get full coverage on Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance

Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven  Yahoo Finance

Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance

Click here to get full coverage on Aytu BioPharma Reports Fiscal 2025 Third Quarter Results - TradingView

Aytu BioPharma Reports Fiscal 2025 Third Quarter Results  TradingView

Aytu BioPharma Reports Fiscal 2025 Third Quarter Results - TradingView

Click here to get full coverage on Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2 - GuruFocus

Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2  GuruFocus

Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2 - GuruFocus

Click here to get full coverage on Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - Stock Titan

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025  Stock Titan

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - Stock Titan

Click here to get full coverage on Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%  simplywall.st

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st

Click here to get full coverage on Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance

Aytu BioPharma Proposes Settlement in Shareholder Lawsuit  Yahoo Finance

Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance

Click here to get full coverage on Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference - ACCESS Newswire

Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference  ACCESS Newswire

Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat - GuruFocus

Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat  GuruFocus

Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat - GuruFocus

Click here to get full coverage on Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025  ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News - GuruFocus

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News  GuruFocus

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News - GuruFocus

Click here to get full coverage on Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational a - GuruFocus

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational a  GuruFocus

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational a - GuruFocus

Click here to get full coverage on Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini

Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd  Wilson Sonsini

Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini

Click here to get full coverage on Aytu BioPharma at Planet MicroCap: Strategic Realignment and Growth - Investing.com

Aytu BioPharma at Planet MicroCap: Strategic Realignment and Growth  Investing.com

Aytu BioPharma at Planet MicroCap: Strategic Realignment and Growth - Investing.com

Click here to get full coverage on AYTU stock touches 52-week low at $1.23 amid market challenges - Investing.com

AYTU stock touches 52-week low at $1.23 amid market challenges  Investing.com

AYTU stock touches 52-week low at $1.23 amid market challenges - Investing.com

Click here to get full coverage on Press Release Distribution & PR Platform - ACCESS Newswire

Press Release Distribution & PR Platform  ACCESS Newswire

Press Release Distribution & PR Platform - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market  ACCESS Newswire

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire

Click here to get full coverage on Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire

Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals  ACCESS Newswire

Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic Growth Amid Challenges - GuruFocus

Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic Growth Amid Challenges  GuruFocus

Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic Growth Amid Challenges - GuruFocus

Click here to get full coverage on Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 | AYTU Stock News - GuruFocus

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 | AYTU Stock News  GuruFocus

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 | AYTU Stock News - GuruFocus

Click here to get full coverage on Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results - ACCESS Newswire

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results  ACCESS Newswire

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results - ACCESS Newswire

Click here to get full coverage on Watchlist #3 - by Sergio Heiber - Microcap Opportunities - substack.com

Watchlist #3 - by Sergio Heiber - Microcap Opportunities  substack.com

Watchlist #3 - by Sergio Heiber - Microcap Opportunities - substack.com

Click here to get full coverage on Aytu BioPharma Announces Indefinite Suspension of AR101 Clinical Development Program for vEDS - The Ehlers Danlos Society

Aytu BioPharma Announces Indefinite Suspension of AR101 Clinical Development Program for vEDS  The Ehlers Danlos Society

Aytu BioPharma Announces Indefinite Suspension of AR101 Clinical Development Program for vEDS - The Ehlers Danlos Society

Click here to get full coverage on Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority - Yahoo Finance

Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority  Yahoo Finance

Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority - Yahoo Finance

Click here to get full coverage on Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe - The Ehlers Danlos Society

Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe  The Ehlers Danlos Society

Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe - The Ehlers Danlos Society

Click here to get full coverage on Aytu to Participate in the Maxim Group Virtual Healthcare Conference - Stock Titan

Aytu to Participate in the Maxim Group Virtual Healthcare Conference  Stock Titan

Aytu to Participate in the Maxim Group Virtual Healthcare Conference - Stock Titan

Click here to get full coverage on Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga

Aytu BioPharma Stock Price, Quotes and Forecasts  Benzinga

Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga

Click here to get full coverage on Check out Aytu Biopharma's stock price (AYTU) in real time - CNBC

Check out Aytu Biopharma's stock price (AYTU) in real time  CNBC

Check out Aytu Biopharma's stock price (AYTU) in real time - CNBC

Click here to get full coverage on Aytu Biopharma vEDS Trial Update - The Ehlers Danlos Society

Aytu Biopharma vEDS Trial Update  The Ehlers Danlos Society

Aytu Biopharma vEDS Trial Update - The Ehlers Danlos Society

Click here to get full coverage on Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome - The Ehlers Danlos Society

Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome  The Ehlers Danlos Society

Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome - The Ehlers Danlos Society

Click here to get full coverage on Opinion | An Experimental Ultraviolet Light Treatment for Covid-19 Takes Political Heat - WSJ

Opinion | An Experimental Ultraviolet Light Treatment for Covid-19 Takes Political Heat  WSJ

Opinion | An Experimental Ultraviolet Light Treatment for Covid-19 Takes Political Heat - WSJ

Click here to get full coverage on Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational - Business Wire

Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational  Business Wire

Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational - Business Wire

Click here to get full coverage on Armistice Capital Must Face Aytu Stock Short-Swing Trade Claims - Bloomberg Law News

Armistice Capital Must Face Aytu Stock Short-Swing Trade Claims  Bloomberg Law News

Armistice Capital Must Face Aytu Stock Short-Swing Trade Claims - Bloomberg Law News

Click here to get full coverage on Pharmaceutical firm Aytu BioScience testing UV light treatment - Washington Times

Pharmaceutical firm Aytu BioScience testing UV light treatment  Washington Times

Pharmaceutical firm Aytu BioScience testing UV light treatment - Washington Times

Click here to get full coverage on 2-minute COVID-19 test results? Denver-area company wants to deliver that promise - 9News

2-minute COVID-19 test results? Denver-area company wants to deliver that promise  9News

2-minute COVID-19 test results? Denver-area company wants to deliver that promise - 9News

Click here to get full coverage on UVA Light Reduced Virus Loads in COVID-19 Patients - Cedars-Sinai

UVA Light Reduced Virus Loads in COVID-19 Patients  Cedars-Sinai

UVA Light Reduced Virus Loads in COVID-19 Patients - Cedars-Sinai

Click here to get full coverage on Grand Prairie-based Neos Therapeutics is merging with a Colorado pharma company - Dallas News

Grand Prairie-based Neos Therapeutics is merging with a Colorado pharma company  Dallas News

Grand Prairie-based Neos Therapeutics is merging with a Colorado pharma company - Dallas News

Click here to get full coverage on COVID-19 antibody test plan shelved over accuracy questions - AspenTimes.com

COVID-19 antibody test plan shelved over accuracy questions  AspenTimes.com

COVID-19 antibody test plan shelved over accuracy questions - AspenTimes.com

Click here to get full coverage on Aytu's Natesto Is Set To Take The $3.8 Billion TRT Market While Lipocine And Clarus Therapeutics Fail - Seeking Alpha

Aytu's Natesto Is Set To Take The $3.8 Billion TRT Market While Lipocine And Clarus Therapeutics Fail  Seeking Alpha

Aytu's Natesto Is Set To Take The $3.8 Billion TRT Market While Lipocine And Clarus Therapeutics Fail - Seeking Alpha

Click here to get full coverage on Fact check: COVID-19 UV light treatment is being studied — not yet in use — in Los Angeles - USA Today

Fact check: COVID-19 UV light treatment is being studied — not yet in use — in Los Angeles  USA Today

Fact check: COVID-19 UV light treatment is being studied — not yet in use — in Los Angeles - USA Today

Click here to get full coverage on UV light, respiratory catheter for COVID-19 from Cedars-Sinai seeking emergency use - BioWorld MedTech

UV light, respiratory catheter for COVID-19 from Cedars-Sinai seeking emergency use  BioWorld MedTech

UV light, respiratory catheter for COVID-19 from Cedars-Sinai seeking emergency use - BioWorld MedTech

Click here to get full coverage on Akeso Forms $100 Million JV with CTTQ to Develop PD-1 Candidate - NAI500

Akeso Forms $100 Million JV with CTTQ to Develop PD-1 Candidate  NAI500

Akeso Forms $100 Million JV with CTTQ to Develop PD-1 Candidate - NAI500

Click here to get full coverage on FDA approves expanded label for Regeneron/Sanofi’s Dupixent - NAI500

FDA approves expanded label for Regeneron/Sanofi’s Dupixent  NAI500

FDA approves expanded label for Regeneron/Sanofi’s Dupixent - NAI500

Click here to get full coverage on WuXi AppTec Leads Investment in Insilico, an AI Drug Discovery Company - NAI500

WuXi AppTec Leads Investment in Insilico, an AI Drug Discovery Company  NAI500

WuXi AppTec Leads Investment in Insilico, an AI Drug Discovery Company - NAI500

Click here to get full coverage on WuXi AppTec Files for $1 Billion-Plus IPO in Hong Kong - NAI500

WuXi AppTec Files for $1 Billion-Plus IPO in Hong Kong  NAI500

WuXi AppTec Files for $1 Billion-Plus IPO in Hong Kong - NAI500

Click here to get full coverage on Qyuns Therapeutics Announces $20 Million Series B for Autoimmune Treatments - NAI500

Qyuns Therapeutics Announces $20 Million Series B for Autoimmune Treatments  NAI500

Qyuns Therapeutics Announces $20 Million Series B for Autoimmune Treatments - NAI500

Click here to get full coverage on Shanghai Miracogen Signs $125 Million Deal to Use Synaffix ADC Technologies - NAI500

Shanghai Miracogen Signs $125 Million Deal to Use Synaffix ADC Technologies  NAI500

Aytu BioScience Inc (AYTU)

Price Chart

Key Statistics

Technicals

About AYTU

Latest News

Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks

Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats E - GuruFocus

Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Advanced Charts

Top Gainers

Top Losers